Navigation Links
For Moderate to Severe Psoriasis, Thought Leaders' Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
Date:6/24/2013

BURLINGTON, Mass., June 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists in the United States and Europe agree that a drug's effect on psoriatic plaques at 12-16 weeks is one of the attributes that most influences their prescribing decisions in moderate to severe psoriasis. Clinical data and the opinions of interviewed thought leaders indicate that the emerging biologics with novel mechanisms of action that target IL-17 have the potential to offer improvements over sales-leading adalimumab (AbbVie/Eisai's Humira) on this attribute.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase report entitled Which Clinical Attributes Will Most Effectively Position Emerging Agents Against the Market Leader, Adalimumab? also finds that surveyed U.S. and European dermatologists and U.S. managed care organization (MCO) pharmacy directors consider therapies with a lower risk of serious infections than current therapies to be one of the greatest unmet needs in moderate to severe psoriasis. Interviewed thought leaders do not believe any emerging therapy has yet demonstrated clear potential to fulfill this unmet need. However, they are optimistic that agents with more-targeted mechanisms of action, including the IL-17 inhibitors, may offer improved safety compared to those that target multiple molecules or molecules that affect multiple downstream pathways.

The findings also reveal that more MCO pharmacy directors are willing to grant favorable formulary status to therapies that offer improvements in safety compared to the number who would grant this status to agent
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
2. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
3. Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimers Disease
4. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
5. AG Mednet CEO Abraham Gutman to Moderate Disruptive Technologies Session at CenterWatch Forum on Optimizing Clinical Research Performance
6. Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost
7. Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
8. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
9. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
10. Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
11. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, Inc. ... a strategic collaboration to discover and develop antisense ... new collaboration builds on a broad existing relationship ... approach in these therapeutic areas using novel RNA-targeted ... use of its antisense technology to diseases of ...
(Date:7/31/2015)... N.C. , July 31, 2015  In today,s ... customers who are increasingly mobile, increasingly connected, and increasingly ... growing variety of customer interaction channels and tools is ... including social media. According to research ... over the counter (OTC) segment in a call center ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
... Wash., Oct. 21, 2011 Evergreen Healthcare today announced ... Care Excellence Awards for 2012 from HealthGrades, placing it ... its superior patient outcomes and significantly reduced mortality rates ... the third consecutive year, Evergreen was honored with HealthGrades, ...
... Fla., Oct. 21, 2011 Boca Pharmacal, Inc., today announced ... Abbreviated New Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 ... 1 mg and Robinul Forte Tablets, 2 mg, distributed by ... adjunctive therapy in the treatment of peptic ulcers. ...
Cached Medicine Technology:Evergreen Named One of America's 100 Best Hospitals for Stroke Care 2Evergreen Named One of America's 100 Best Hospitals for Stroke Care 3Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets 2
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number ... according to market research compiled for the National Association of Dental Laboratories ( ... Labor, Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists ...
(Date:8/3/2015)... ... , ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical ... in August. The new facility is licensed under Dignity Health Arizona General ... Baldwin is an excellent leader and will ensure our new freestanding emergency room delivers ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted to have ... diabetes after many years of suffering and using medications with strong side effects. This ... ask for extra time off or wait longer hours in the waiting rooms. Instead, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Foot and Ankle Specialists of the ... creating the largest medical practice in the Mid-Atlantic region – and the second largest ... locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland native. She grew ...
(Date:8/3/2015)... ... , ... The American Institute of Architects (AIA) ... across a wide range of initiatives ranging from code development and compliance to ... combined membership, consisting of practicing design professionals, code officials, and the building industry ...
Breaking Medicine News(10 mins):Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3
... June 9 Par Pharmaceutical Companies, Inc. (NYSE: ... spray to the trade. Calcitonin-salmon nasal spray is a ... sales of Miacalcin were approximately $112 million in 2008, according ... Important information about calcitonin-salmon nasal spray , , ...
... Offers One Stop for Market-Specific Managed Care Enrollment ... and Health Plan Trends , , NASHVILLE, ... managed care market intelligence, reports that commercial pharmacy ... the state level than commercial medical benefit enrollment. ...
... solid reputation within industry , , HOFFMAN ESTATES, ... Spine, Inc. announced today that it has appointed Todd P. ... Fanning has held senior sales and marketing positions at well ... orthopaedic industries, including Spinal Concepts (now part of Zimmer ...
... Selected as Best EHR/PM System to Help Physicians, Organization ... , , DALLAS, June 9 ... software solutions for physician practices, announced today that after ... Physicians, Organization of the University Medical Center ...
... Cyrus at the 20th Annual A Time For Heroes Family ... AIDS Foundation , , LOS ANGELES, June 9 ... 20th annual A Time For Heroes Family Picnic, held June ... Pediatric AIDS Foundation. More than 80 of Hollywood,s best-known names ...
... Kennedy On Some Points, Denise Gott Agrees that Everyone ... Acute Ones , , KIRKLAND, Wash., June 9 ... terms with a Democratic Congress on health reform, according ... praise on Senator Edward Kennedy (D-MA) for his crusading ...
Cached Medicine News:Health News:Par Pharmaceutical Begins Shipment of Generic Miacalcin(R) 2Health News:Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment 2Health News:The Physicians' Organization of the University Medical Center at Princeton Chooses iMedica's EHR and Practice Management Solutions 2Health News:The Physicians' Organization of the University Medical Center at Princeton Chooses iMedica's EHR and Practice Management Solutions 3Health News:Celebrities Come Together to Fight Pediatric AIDS 2Health News:Celebrities Come Together to Fight Pediatric AIDS 3Health News:Insurance Leader Praises Senator Kennedy for Promoting Long-Term Care Aid for All Americans as Part of Health Reform 2Health News:Insurance Leader Praises Senator Kennedy for Promoting Long-Term Care Aid for All Americans as Part of Health Reform 3Health News:Insurance Leader Praises Senator Kennedy for Promoting Long-Term Care Aid for All Americans as Part of Health Reform 4
... catheter is a coaxial, ... is made of PEBAX ... in the inner balloon ... markings enhance the visibility ...
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
Medicine Products: